Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Improvement in Scalp-Related Quality of Life and Symptoms in the Phase 3b 4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled PSORIATYK SCALP Trial. J of Skin 2024, 8 (6), s425. https://doi.org/10.25251/skin.8.supp.425.